October 7, 2025 — Leads & Copy — Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) is hosting its 2025 Innovation Day in New York City today, where company leaders will highlight recent independent launches, a growing pipeline of wholly-owned medicines, innovative technology, and a clear path to sustained positive cash flow. A leading physician will also discuss the current treatment landscape and unmet needs for severe hypertriglyceridemia (sHTG) in anticipation of a potential olezarsen launch.
Ionis CEO Brett P. Monia, Ph.D., noted the achievement of two independent launches in less than nine months, emphasizing the company’s progress toward transforming human health via RNA-targeted medicines. The company anticipates two more independent launches in 2026 and four partner launches by the end of 2027.
The Innovation Day event, which includes presentations on Ionis’ cardiometabolic and neurology portfolios, also covers partnered programs and marketed medicines, such as TRYNGOLZA® (olezarsen) for familial chylomicronemia syndrome (FCS) and DAWNZERA™ (donidalorsen) for hereditary angioedema (HAE).
Ionis has a strong financial foundation with ~$2B in cash and short-term investments (2025 financial guidance), efficient capital structure and a strong history of disciplined capital management.
Robert D. Fishberg, M.D., cardiologist with Atlantic Medical Group in Springfield, NJ and assistant clinical professor of medicine at the Sidney Kimmel Medical College, Thomas Jefferson University.
Source: Ionis Pharmaceuticals, Inc.
